Skip to main content

JDRF has now rebranded to Breakthrough T1D.
Our name has changed, our mission has not.

“JDRF research has transformed lives” Theresa May and Nina Wadia talk type 1 diabetes at JDRF fundraiser

JDRF’s Global Research Ambassador, the Rt Hon Theresa May MP, has shared what inspires her to support Breakthrough T1D UK with fellow Ambassador Nina Wadia OBE at an event to raise money for the type 1 diabetes charity.
Breakthrough T1D profile picture
Kate Gerrard 31 May 2022
Theresa May and Nina Wadia

JDRF Global Research Ambassador Theresa May answered questions from the audience about how she managed her type 1 diabetes while in office.

On diagnosis, research and managing type 1 in office

Diagnosed with type 1 diabetes in 2012 when she was Home Secretary, Mrs May became the first world leader with type 1 when she became Prime Minister in 2016. She has been an Ambassador for JDRF since 2020, raising awareness of the condition and championing JDRF’s global research programme.

Speaking at the event, Mrs May said: “Research is vital, and we both know the wide range of research that JDRF funds and supports. It’s enabling us to improve the lives of people with type 1 right now, and to work towards stopping people from developing type 1 in the future.

“The research that JDRF has done has transformed lives.”

Mrs May then answered questions from the audience about how she managed her type 1 diabetes whilst in office, including how she dealt with hypos during long meetings, travelling and attending State Banquets where she could not carb count in advance.

She said: “Formal state banquets aren’t that difficult because they run to a very rigid timetable, so you know exactly when you’re going to eat. Speaking at a dinner event is much harder because you have no idea how quickly the meal will be served.”

In response, Nina warned her: “Don’t ever go to an Indian wedding!”

Type 1 diabetes technology makes a huge difference

Mrs May also talked about the technology that helps her manage type 1.

“The great thing about technology these days is that you’re not worried about testing now and then, because it’s so easy,” she said.

“I use a FreeStyle Libre, which is transformative. Knowing what your blood glucose level is doing at any one moment is crucial, so having the technology to see it clearly on a phone makes a huge difference.”

Nina Wadia, who was awarded an OBE for her services to charity and entertainment in 2020, has supported JDRF since her son, Aidan, was diagnosed with type 1 in 2017.

In contrast to Mrs May, Nina’s son uses both an Omnipod insulin pump and a Dexcom continuous glucose monitor.

She said: “Aidan said he didn’t want wires, so when we were introduced to the Omnipod I said, ‘I’m getting him one of those.’”

Nina has raised significant funds for JDRF research through appearances on Sitting on a Fortune, Celebrity Catchpoint and Celebrity Pointless.

The event was co-sponsored by Abbott and Insulet, and included a fundraising raffle sponsored by Gem Voyager.

Related news

Read more
Female doctor with smiling patient in clinic setting
Research
26 March 2025

Making medical research programmes and clinical trials more accessible and inclusive

Read our top takeaways from the ‘Recruiting to medical research programmes and trials – how can we be smarter and more equitable?’ webinar.

Read more
Islet cells from human donors
Research
17 March 2025

Breakthrough in T1D treatment: Improving islet transplantation

Researchers funded by Breakthrough T1D in the US have published promising new data that could help to improve islet transplantation for people with T1D.

Read more
A researcher looking through a microscope at a kidney on a chip.
News
4 March 2025

UK diabetes and kidney charities establish key research and healthcare recommendations for diabetic kidney disease

A new paper co-authored by Breakthrough T1D, Diabetes UK, and Kidney Research UK has identified six themes to tackle diabetic kidney disease.

Read more
Dr Ana Cruz in her lab
Research
8 January 2025

Breakthrough in T1D treatment: Engineered islets produce insulin without immunosuppression

Sana Biotechnology, a US-based biotech company, has released clinical data showing that the first person receiving engineered islets from deceased donors is now producing insulin without the need for immunosuppressive drugs.